Nakagawa K - Search Results

1

Association between glutathione S-transferase A1, M1 and T1 polymorphisms and hypertension.

Oniki K, Hori M, Takata K, Yokoyama T, Mihara S, Marubayashi T, Nakagawa K. Oniki K, et al. Among authors: nakagawa k. Pharmacogenet Genomics. 2008 Mar;18(3):275-7. doi: 10.1097/FPC.0b013e3282f56176. Pharmacogenet Genomics. 2008. PMID: 18300949

2

Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity.

Ueda K, Ishitsu T, Seo T, Ueda N, Murata T, Hori M, Nakagawa K. Ueda K, et al. Among authors: nakagawa k. Pharmacogenomics. 2007 May;8(5):435-42. doi: 10.2217/14622416.8.5.435. Pharmacogenomics. 2007. PMID: 17465707

3

Combined glutathione S-transferase T1 and M1 positive genotypes afford protection against type 2 diabetes in Japanese.

Hori M, Oniki K, Ueda K, Goto S, Mihara S, Marubayashi T, Nakagawa K. Hori M, et al. Among authors: nakagawa k. Pharmacogenomics. 2007 Oct;8(10):1307-14. doi: 10.2217/14622416.8.10.1307. Pharmacogenomics. 2007. PMID: 17979505

4

Glutathione S-transferase A1 polymorphism as a risk factor for smoking-related type 2 diabetes among Japanese.

Oniki K, Umemoto Y, Nagata R, Hori M, Mihara S, Marubayashi T, Nakagawa K. Oniki K, et al. Among authors: nakagawa k. Toxicol Lett. 2008 May 30;178(3):143-5. doi: 10.1016/j.toxlet.2008.03.004. Epub 2008 Mar 15. Toxicol Lett. 2008. PMID: 18430527

5

Association between combinations of glutathione-S-transferase M1, T1 and P1 genotypes and non-alcoholic fatty liver disease.

Hori M, Oniki K, Nakagawa T, Takata K, Mihara S, Marubayashi T, Nakagawa K. Hori M, et al. Among authors: nakagawa k, nakagawa t. Liver Int. 2009 Feb;29(2):164-8. doi: 10.1111/j.1478-3231.2008.01794.x. Epub 2008 May 19. Liver Int. 2009. PMID: 18492019

6

The combination of mitochondrial low enzyme-activity aldehyde dehydrogenase 2 allele and superoxide dismutase 2 genotypes increases the risk of hypertension in relation to alcohol consumption.

Nakagawa T, Kajiwara A, Saruwatari J, Hamamoto A, Kaku W, Oniki K, Mihara S, Ogata Y, Nakagawa K. Nakagawa T, et al. Among authors: nakagawa k. Pharmacogenet Genomics. 2013 Jan;23(1):34-7. doi: 10.1097/FPC.0b013e32835b1707. Pharmacogenet Genomics. 2013. PMID: 23111423

7

Interactive effects of smoking and glutathione S-transferase polymorphisms on the development of non-alcoholic fatty liver disease.

Oniki K, Hori M, Saruwatari J, Morita K, Kajiwara A, Sakata M, Mihara S, Ogata Y, Nakagawa K. Oniki K, et al. Among authors: nakagawa k. Toxicol Lett. 2013 Jul 4;220(2):143-9. doi: 10.1016/j.toxlet.2013.04.019. Epub 2013 Apr 30. Toxicol Lett. 2013. PMID: 23643483

8

Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy.

Takata K, Saruwatari J, Nakada N, Nakagawa M, Fukuda K, Tanaka F, Takenaka S, Mihara S, Marubayashi T, Nakagawa K. Takata K, et al. Among authors: nakagawa k, nakagawa m. Eur J Clin Pharmacol. 2006 Jan;62(1):23-8. doi: 10.1007/s00228-005-0057-z. Epub 2005 Dec 30. Eur J Clin Pharmacol. 2006. PMID: 16385402

9

Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.

Saruwatari J, Matsunaga M, Ikeda K, Nakao M, Oniki K, Seo T, Mihara S, Marubayashi T, Kamataki T, Nakagawa K. Saruwatari J, et al. Among authors: nakagawa k. Eur J Clin Pharmacol. 2006 Dec;62(12):995-1001. doi: 10.1007/s00228-006-0210-3. Epub 2006 Nov 7. Eur J Clin Pharmacol. 2006. PMID: 17089107

10

Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.

Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, Nakagawa K. Seo T, et al. Among authors: nakagawa k. Pharmacogenomics. 2008 May;9(5):527-37. doi: 10.2217/14622416.9.5.527. Pharmacogenomics. 2008. PMID: 18466100

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,697 results

Search Page